Rosen Theodore, Stein Gold Linda F
Professor of Dermatology Baylor College of Medicine Houston, Texas.
Director of Dermatology Research Henry Ford Health System Detroit, Michigan.
Semin Cutan Med Surg. 2016 Mar;35(3 Suppl 3):S51-5. doi: 10.12788/j.sder.2016.009.
In 1996, oral terbinafine joined itraconazole and fluconazole on the short list of systemic medications that could be used to treat onychomycosis (although fluconazole was not approved for this indication by the US Food and Drug Administration [FDA], it was commonly used for this purpose). In 1999, ciclopirox was the first topical treatment to be FDA approved. The addition of the topical antifungal agents efinaconazole and tavaborole in 2014 expanded the roster of medications available to more effectively manage onychomycosis in a wide range of patients, including those for whom comorbid conditions, concomitant medications, or patient preference limited the use of systemic antifungals.
1996年，口服特比萘芬与伊曲康唑和氟康唑一起，成为可用于治疗甲癣的少数几种全身性药物（尽管氟康唑未获美国食品药品监督管理局[FDA]批准用于此适应症，但它通常用于此目的）。1999年，环吡酮成为首个获得FDA批准的局部治疗药物。2014年，新型局部抗真菌药物艾氟康唑和他氟硼酸盐的加入，扩大了可用于更有效治疗广泛患者甲癣的药物种类，包括那些因合并症、同时服用的药物或患者偏好而限制使用全身性抗真菌药物治疗的患者群体。
